证券代码：002980 证券简称：华盛昌 深圳市华盛昌科技实业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|--------------|------------| | | 特定对象调研 | 分析师会议 | | 投资者关系活动 | 媒体采访 | 业绩说明会 | | 类别 | 新闻发布会 | 路演活动 | | | 现场参观 | | 其他 参与单位名称及 人员姓名 线上参与公司 2022 年度网上业绩说明会的全体投资者 时间 2023 年 5 月 16 日 15:00-17:00 地点 价值在线（www.ir-online.cn） 董事长、总经理：袁剑敏 上市公司接待人 财务总监：刘海琴 员姓名 独立董事：李学金 董事会秘书：任欢 1、今年有分红吗？ 答：尊敬的投资者，您好!考虑到公司未来可持续发展， 同时兼顾对投资者的合理回报，结合公司当前实际经营、现金 投资者关系活动 流状况和资本公积情况，根据公司章程中利润分配政策相关规 主要内容介绍 定，提议 2022 年年度利润分配方案预案为：以公司最新总股 本 13,635.49 万股为基数，向全体股东 ...

证券代码：002980 证券简称：华盛昌 公告编号：2023-034 深圳市华盛昌科技实业股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及公司全体董事会成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 深圳市华盛昌科技实业股份有限公司（以下简称"公司"）2022年年度报告 于2023年4月29日在巨潮资讯网等媒体予以发布，为加强投资者关系管理，便于 广大投资者更全面、深入了解公司2022年年度报告和经营情况，公司定于2023年 5月16日（星期二）下午15:00-17:00举办2022年度业绩说明会。本次业绩说明会 将采用网络远程的方式举行，具体情况如下： 一、业绩说明会安排 1、召开时间：2023年5月16日（星期二）下午15:00-17:00。 欢迎广大投资者积极参与。在此，公司对长期以来关心和支持公司发展并积 极提出建议的投资者表示衷心感谢。 特此公告。 2、召开地点：价值在线（www.ir-online.cn）。 3、召开方式：网络互动。 4、参会人员：公司董事长兼总经理袁剑敏先生、财务总监刘海琴女士、独 立董事李学金先生、董事会秘书任欢女士。（如有特 ...

深圳市华盛昌科技实业股份有限公司 2023 年第一季度报告 证券代码：002980 证券简称：华盛昌 公告编号：2023-025 深圳市华盛昌科技实业股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责 任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保 证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 151,231,759.11 | 148,818,081.86 | 1.62% | | 归属于上市公司股东的净利润（元） | 21,062,048.07 | 25,385,8 ...

Financial Performance - The company's operating revenue for 2022 was CNY 596,775,379.37, a decrease of 19.36% compared to CNY 740,051,644.74 in 2021[18]. - The net profit attributable to shareholders for 2022 was CNY 98,242,651.87, down 34.02% from CNY 148,888,059.88 in the previous year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 87,468,040.16, a decrease of 32.97% from CNY 130,489,628.25 in 2021[18]. - The basic earnings per share for 2022 was CNY 0.74, down 33.93% from CNY 1.12 in 2021[18]. - The total assets at the end of 2022 were CNY 1,159,754,497.49, a decrease of 3.07% from CNY 1,196,465,650.69 at the end of 2021[18]. - The net assets attributable to shareholders at the end of 2022 were CNY 1,015,841,691.22, down 4.35% from CNY 1,062,074,049.72 in 2021[18]. - The net cash flow from operating activities increased by 60.32% to CNY 52,177,675.36 from CNY 32,545,946.89 in the previous year[18]. - The company reported a net profit attributable to shareholders of 98.24 million yuan, a year-on-year decrease of 34.02%[19]. - The total operating costs for the main business amounted to CNY 343,236,390.61, a decrease of 21.68% compared to CNY 438,251,821.06 in the previous year[104]. - The revenue from the instrument manufacturing industry was ¥571.59 million, accounting for 95.78% of total revenue, with a year-on-year decline of 22.07%[98]. - The company achieved a gross margin of 39.95% in the instrument manufacturing sector, which decreased by 0.30% compared to the previous year[99]. - The company's overseas revenue was ¥515.99 million, representing 86.46% of total revenue, down 22.51% from the previous year[98]. - The domestic revenue increased by 8.94% to ¥80.78 million, accounting for 13.54% of total revenue[98]. Research and Development - R&D expenses increased to 75.31 million yuan from 58.31 million yuan, representing a year-on-year growth of 29.15%[20]. - The company is focused on enhancing its R&D capabilities in high-end products and technologies, aligning with national policies supporting the instrument manufacturing industry[30]. - The company aims to enhance its innovation capabilities in precision instruments, focusing on key components like oscilloscopes and spectrum analyzers[31]. - The company has established a MEMS/NEMS R&D base to improve its technological competitiveness in sensor development[113]. - The number of R&D personnel rose to 190, a 10.47% increase from 2021, with a significant rise in younger staff under 30 years old by 118.92%[113]. - R&D investment increased by 29.15% to ¥75,309,692.20 in 2022, accounting for 12.62% of operating revenue[113]. - The company is actively enhancing its investment in R&D for in vitro diagnostic instruments and reagents, with key products under development including a nucleic acid extraction detection integrated machine capable of completing 384 target detections in 1 hour[63]. Market and Product Development - The company is actively expanding into emerging markets such as medical testing and renewable energy[36]. - The company has launched innovative products, including a multifunctional digital multimeter with an integrated thermal imaging feature[38]. - The company is implementing a dual-driven strategy of "technology + market" to enhance its market presence[35]. - The company has developed a series of "thermal imager +" products, combining thermal imaging with multimeters, clamp meters, and insulation testers, creating significant technological advantages[45]. - The company has developed multiple rapid test kits for respiratory infectious diseases, including five products that have received EU professional CE certification[61]. - The company is focused on expanding its market presence through new product development and strategic investments in technology[112]. - The company is actively pursuing opportunities for market expansion and potential mergers and acquisitions to drive growth[184]. Governance and Management - The company maintained a robust governance structure, ensuring compliance with relevant laws and regulations, which supports its sustainable development and shareholder rights[160]. - The company held four shareholder meetings during the reporting period, ensuring equal treatment of all shareholders and adherence to legal voting procedures[161]. - The board of directors consists of 8 members, including 3 independent directors, and held 6 meetings during the reporting period[163]. - The supervisory board comprises 3 members, including 1 employee representative, and also held 6 meetings during the reporting period[164]. - The company emphasizes the protection of stakeholders' rights and maintains communication with shareholders, employees, and society[166]. - The company has established a complete and independent financial accounting system, with no shared bank accounts with controlling shareholders[171]. - The company has a fully independent research, procurement, production, and sales system, with no reliance on controlling shareholders for operations[174]. Challenges and Risks - The company faced multiple production stoppages during the reporting period, impacting overall operations[18]. - The company faces uncertainty regarding its ability to continue as a going concern, as indicated by negative net profits over the last three accounting years[20]. - The company faces risks from international trade policies and exchange rate fluctuations, which may impact overseas business performance[153]. - The company is addressing raw material price volatility risks by optimizing supply chain resources and controlling costs through technology upgrades[154]. Employee and Training - The total number of employees at the end of the reporting period is 1,352, with 1,177 from the parent company and 175 from major subsidiaries[196]. - The professional composition includes 938 production personnel, 120 sales personnel, 190 technical personnel, 30 financial personnel, and 74 administrative personnel[196]. - A comprehensive annual training plan is established to improve employee quality and work efficiency, covering various aspects such as professional skills and safety management[199]. - The company emphasizes a diversified incentive mechanism based on team and individual performance, enhancing employee motivation and creativity[197]. Future Outlook - The company aims to enhance its core business while further deepening existing industries and clients, focusing on structural optimization and transformation[146]. - The company will continue to increase R&D investment, emphasizing technology innovation and the accumulation of proprietary technology, with a focus on aligning R&D with market demand[147]. - The company plans to strengthen brand building through various channels, aiming to enhance its market share and competitiveness[148].

证券代码：002980 证券简称：华盛昌 深圳市华盛昌科技实业股份有限公司 投资者关系活动记录表 编号：2020-001 | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------|----------------------------|------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | □ □ 媒体采访 □业绩说明会 | 特定对象调研 √分析师会议 | | | | | | | 投资者关系活动 | □ 新闻发布会 □路演活动 | | | | | | | | 类别 | □ 现场参观 | | | | | | | | | □ | 其他 （请文字说明其他活动内容） | | | | | | | | 国海证券：傅鸿浩 | | | | | | | | 参与单位名称及 人员姓名 | 太平洋证券：李仁波、曾博文 | | | | | | | | | 安信 ...

证券代码：002980 证券简称：华盛昌 深圳市华盛昌科技实业股份有限公司 投资者关系活动记录表 编号：2020-002 | --- | --- | --- | --- | |----------------|--------------------------|--------------------------------------------|---------------------------------------------------| | | □ | 特定对象调研 √分析师会议 | | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | | 类别 | □ | 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | □ | 其他 （请文字说明其他活动内容） | | | 参与单位名称及 | | Platinum Investment Management：Alan Zhang | | | 人员姓名 | | | | | 时间 | 2020 年 11 月 26 | 日 | | | 地点 | 公司会议室 | | | | 上市公司接待人 | 董事长、总经理：袁剑敏 | | ...

证券代码：002980 证券简称：华盛昌 深圳市华盛昌科技实业股份有限公司 投资者关系活动记录表 编号：2020-003 | --- | --- | --- | |----------------|--------------------------|------------------------------------------------------| | | □ | 特定对象调研 √分析师会议 | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | 类别 | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 华泰证券：黄波、陈家辉 | | | 人员姓名 | | | | 时间 | 2020 年 12 月 10 | 日 | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事长、总经理：袁剑敏 | | | 员姓名 | 董事会秘书：任欢 | | | 投资者关系活动 | 1 | 、关于未来在医疗领域的开拓 | | 主要内容介绍 | | 答：目前，全民健康意识在逐步增强，疫情防控工作有 | | | ...

证券代码：002980 证券简称：华盛昌 编号：2021-002 深圳市华盛昌科技实业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|--------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | √ 特定对象调研 | □ 分析师会议 | | 投资者关系活动 | □ ...